Health-care companies rose after strong earnings from one obesity-drug maker. Eli Lilly shares rose after it reiterated its forecast for 32% 2025 revenue growth, amid rising demand for its Zepbound ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

With the FDA quietly rolling back DEI initiatives under Trump’s latest executive order, experts warn that underrepresentation ...

ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder. ResMed makes continuous positive ...

Healthcare stocks have been under the weather for the past few years, underperforming the broader market’s rally despite ...

Pete Yonkman, president of Cook Group and Cook Medical, was among the speakers Monday at the official launch of the new ...

Industry watchers expect global biotech mergers and acquisition activity to strengthen in 2025 after a subdued 2024, aiding ...

Eli Lilly (NYSE: LLY) sells a broad variety of drugs across ... This player's units include medical devices, diagnostics, nutrition, and established pharmaceuticals. What's great about this is, if one ...

Shelby Knowles / Bloomberg via Getty Images Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for sleep apnea last month. Weight loss ...

In other news, Eli Lilly has partnered with Purdue University and Merck to advance medical manufacturing technologies. The goal is to improve how medicines are made by using the latest ...

Visible healing of the intestinal lining was observed in 46% of subjects treated with the therapy. Credit: SewCreamStudio/Shutterstock. Eli Lilly has received ...